SPB and RAGE increases in the plasma during cardiopulmonary by-pass: a pilot study

words count: 185

[1]  T. Stewart,et al.  Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. , 2009, American journal of respiratory and critical care medicine.

[2]  S. Toyabe,et al.  Protective mechanism of ultrafiltration against cardiopulmonary bypass-induced lung injury. , 2009, Transplantation proceedings.

[3]  E. Tremoli,et al.  Circulating Plasma Surfactant Protein Type B as Biological Marker of Alveolar-Capillary Barrier Damage in Chronic Heart Failure , 2009, Circulation. Heart failure.

[4]  J. Kesecioglu,et al.  Exogenous surfactant attenuation of ischemia-reperfusion injury in the lung through alteration of inflammatory and apoptotic factors. , 2009, The Journal of thoracic and cardiovascular surgery.

[5]  D. Andreini,et al.  Alveolar membrane conductance decreases as BNP increases during exercise in heart failure. Rationale for BNP in the evaluation of dyspnea. , 2009, Journal of cardiac failure.

[6]  T. Loop,et al.  Reduced pulmonary inflammatory response during cardiopulmonary bypass: effects of combined pulmonary perfusion and carbon monoxide inhalation. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[7]  T. Mukherjee,et al.  Implication of receptor for advanced glycation end product (RAGE) in pulmonary health and pathophysiology , 2008, Respiratory Physiology & Neurobiology.

[8]  J. Pérez-Gil,et al.  Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions. , 2008, Biochimica et biophysica acta.

[9]  P. Parsons,et al.  Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury , 2008, Thorax.

[10]  G. Enhorning.  Surfactant in airway disease. , 2008, Chest.

[11]  A. Arroliga,et al.  Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  P. Karaca,et al.  Cardioprotective effect of aprotinin on myocardial ischemia/reperfusion injury during cardiopulmonary bypass. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[13]  S. D. De Hert,et al.  Effects of sevoflurane on biomechanical markers of hepatic and renal dysfunction after coronary artery surgery. , 2006, Journal of cardiothoracic and vascular anesthesia.

[14]  J. Pérez-Gil,et al.  Protein-lipid interactions and surface activity in the pulmonary surfactant system. , 2006, Chemistry and physics of lipids.

[15]  M. Matthay,et al.  Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. , 2006, American journal of respiratory and critical care medicine.

[16]  A. Bersten,et al.  CIRCULATING SURFACTANT PROTEIN‐B LEVELS INCREASE ACUTELY IN RESPONSE TO EXERCISE‐INDUCED LEFT VENTRICULAR DYSFUNCTION , 2005, Clinical and experimental pharmacology & physiology.

[17]  P. Aylward,et al.  Plasma Surfactant Protein-B: A Novel Biomarker in Chronic Heart Failure , 2004, Circulation.

[18]  A. Bersten,et al.  Prolonged alveolocapillary barrier damage after acute cardiogenic pulmonary edema* , 2003, Critical care medicine.

[19]  W. Seeger,et al.  Changes in biochemical and biophysical surfactant properties with cardiopulmonary bypass in children , 2003, Critical care medicine.

[20]  K. Meyer.  Lung Surfactants: Basic Science and Clinical Applications , 2002 .

[21]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[22]  T. Weaver,et al.  Function of surfactant proteins B and C. , 2001, Annual review of physiology.

[23]  M. Guazzi,et al.  Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. , 2000, American heart journal.

[24]  V. D’Agati,et al.  Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. , 2000, Journal of the American Society of Nephrology : JASN.

[25]  J. Whitsett,et al.  Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. , 1999, American journal of respiratory and critical care medicine.

[26]  F L Grover,et al.  The Society of Thoracic Surgeons National Database: current status and future directions. , 1999, The Annals of thoracic surgery.

[27]  R. Salamon,et al.  Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[28]  M. Derrick,et al.  Structure and properties of surfactant protein B. , 1998, Biochimica et biophysica acta.

[29]  T. Weaver,et al.  Synthesis, processing and secretion of surfactant proteins B and C. , 1998, Biochimica et biophysica acta.

[30]  J. Goerke,et al.  Pulmonary surfactant: functions and molecular composition. , 1998, Biochimica et biophysica acta.

[31]  F. Péronnet,et al.  Lung function and exercise gas exchange in chronic heart failure. , 1998, Circulation.

[32]  A. Bersten,et al.  Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure. , 1997, American journal of respiratory and critical care medicine.

[33]  G. Rocker,et al.  The Systemic Inflammatory Response to Cardiopulmonary Bypass: Pathophysiological, Therapeutic, and Pharmacological Considerations , 1997, Anesthesia and analgesia.

[34]  T. Evans,et al.  Pulmonary vascular permeability after cardiopulmonary bypass and its relationship to oxidative stress. , 1997, Critical care medicine.

[35]  M. Pollack,et al.  Surfactant content in children with inflammatory lung disease. , 1996, Critical care medicine.

[36]  G. Hill.  The Inflammatory Response to Cardiopulmonary Bypass , 1996, International anesthesiology clinics.

[37]  T. Chua,et al.  The lungs in chronic heart failure. , 1995, European heart journal.

[38]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[39]  T. Evans,et al.  Changes in lung function and pulmonary capillary permeability after cardiopulmonary bypass , 1992, Critical care medicine.

[40]  M. Williams,et al.  Effects of surfactant apolipoproteins on liposome structure: implications for tubular myelin formation. , 1992, The American journal of physiology.

[41]  K. Sullivan,et al.  Adult respiratory distress syndrome following cardiopulmonary bypass: incidence and prediction , 1992, Anaesthesia.

[42]  J. Whitsett,et al.  Processing of hydrophobic pulmonary surfactant protein B in rat type II cells. , 1989, The American journal of physiology.

[43]  H. Schägger,et al.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. , 1987, Analytical biochemistry.

[44]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.